Abstract
Hepatitis B Virus (HBV) is one of the most prevalent viral infections of human worldwide. The therapies are limited in the clinical context because of negative side effects of interferons and the development of viral resistance to the nucleoside/nucleotide inhibitors. In this review, we summarize the recent advances in design and development of potent anti-HBV inhibitors from natural sources and synthetic compounds, targeting different steps in the life cycle of HBV. We attempt to emphasize the major structural modifications, mechanisms of action and computer-aided docking analysis of novel potent inhibitors that need to be addressed in the future to design potent anti-HBV molecules.
Financial & competing interests disclosure
The financial support from the National Natural Science Foundation of China (NSFC No. 81273354; 81102320; 30873133; 30772629; 30371686), Key Project of NSFC for International Cooperation (No. 81420108027; 30910103908), Research Fund for the Doctoral Program of Higher Education of China (No. 20110131130005; 20110131120037), Natural Science Foundation of Shandong Province (ZR2009CM016), National Natural Science Foundation of China, and Research Fund for International Young Scientists (NSFC No. 21350110215, awarded to RD). The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.
No writing assistance was utilized in the production of this manuscript.